<DOC>
	<DOCNO>NCT02581865</DOCNO>
	<brief_summary>Phase 2 , double-blind , placebo-controlled study ass safety efficacy NBI-98854 administer daily ( qd ) total 8 week treatment . This study enroll approximately 90 male female subject clinically diagnose Tourette Syndrome .</brief_summary>
	<brief_title>Safety Efficacy Study NBI-98854 Adults With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>1 . Have clinical diagnosis Tourette Syndrome ( TS ) 2 . Have least moderate tic severity 3 . Have TS symptom impair school , occupational , and/or social function 4 . If use maintenance medication ( ) TS TS spectrum diagnosis ( e.g . obsessivecompulsive disorder [ OCD ] , AttentionDeficit Hyperactivity Disorder [ ADHD ] ) , stable dos 5 . Be good general health 6 . Have negative urine drug screen amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , negative alcohol screen 7 . Subjects childbearing potential practice total abstinence must agree use hormonal two form nonhormonal contraception ( dual contraception ) consistently screen , treatment followup period study 1 . Have active , clinically significant unstable medical condition within 1 month prior screen 2 . Have know history long QT syndrome cardiac tachyarrhythmia 3 . Have know history neuroleptic malignant syndrome 4 . Have cancer diagnosis within 3 year prior screen ( exception allow ) 5 . Have allergy , hypersensitivity , intolerance VMAT2 inhibitor 6 . Have know history substance dependence , substance ( drug ) alcohol abuse 7 . Have significant risk suicidal violent behavior 8 . Are currently pregnant breastfeed 9 . Have initiate Comprehensive Behavioral Intervention Tics ( CBIT ) screen period baseline plan initiate CBIT study 10 . Have receive investigational drug within 30 day screen plan use investigational drug ( NBI98854 ) study 11 . Have blood loss â‰¥550 mL donate blood within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>